mRNA-HPV Therapeutic Vaccine Encoding E6 and E7 Improves Therapeutic Potential in HPV-mediated Cancer

Abstract The viral E6 and E7 oncoproteins of human papillomavirus (HPV) are strongly associated with cervical cancer. We developed assessed the efficacy an mRNA-HPV therapeutic vaccine (mHTV), containing proteins, in C57BL/J mice. mHTV generated robust T cell-mediated immune responses induced short-lived effector tetramer-specific cells. immunization significantly suppressed tumor growth mice implanted TC-1 cells improved overall survival. re-transplantation into that survived primary challenge after vaccination led to complete inhibition progression all mHTV-treated This showed can effectively suppress cancer recurrence. also increased number tumor-infiltrating lymphocytes tissues. When were vaccination, most immunized protected from challenge. In conclusion, considerable potential as not only a vaccine, by efficiently killing cells, but prophylactic enhancing responses. Brain Korea 21 Plus Program, Partially supported. Ministry Food Drug Safety grant (grant 22213MFDS421) National Research Foundation (NRF) NRF-2021M3E5E3080558)